Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis.
GRADE recommendation
Thyroid cancer
radioiodine
radiotherapy
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
17
3
2021
medline:
15
12
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated. The panel of the Italian Association of Radiotherapy and Clinical Oncology developed a clinical recommendation on the addition of EBRT to radioiodine after surgery for locally advanced differentiated thyroid cancer by using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the Evidence to Decision framework. A systematic review with meta-analysis about this topic was conducted with a focus on outcome of benefits and toxicity. Locoregional control was improved by EBRT while no considerable toxicity impact was reported. The panel judged uncertain the benefit/harms balance; final recommendation was conditional both for EBRT + radioiodine and radioiodine alone in the adjuvant setting.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated.
METHODS
METHODS
The panel of the Italian Association of Radiotherapy and Clinical Oncology developed a clinical recommendation on the addition of EBRT to radioiodine after surgery for locally advanced differentiated thyroid cancer by using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the Evidence to Decision framework. A systematic review with meta-analysis about this topic was conducted with a focus on outcome of benefits and toxicity.
RESULTS
RESULTS
Locoregional control was improved by EBRT while no considerable toxicity impact was reported.
CONCLUSION
CONCLUSIONS
The panel judged uncertain the benefit/harms balance; final recommendation was conditional both for EBRT + radioiodine and radioiodine alone in the adjuvant setting.
Identifiants
pubmed: 33722108
doi: 10.1177/0300891621996817
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM